Health Catalyst (HCAT) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary
Event summary combining transcript, slides, and related documents.
43rd Annual J.P. Morgan Healthcare Conference 2025 summary
10 Jan, 2026Strategic focus and business overview
Provides data and analytics technology and services to healthcare organizations, with revenue split evenly across data platform, applications, and services.
Mission centers on measurable, data-informed healthcare improvement, supported by a highly engaged team and recognized as a top workplace over 100 times from 2015–2024.
Serves over 1,000 clients, including major health systems, academic centers, and insurers, with 90% recurring revenue and high client retention rates (100–112%).
Recognized as an industry leader in healthcare data and analytics, offering a comprehensive solution across platform, apps, and services.
Team member engagement is a core driver, with Gallup scores in the 94th percentile, supporting high client engagement and loyalty.
Technology and product innovation
Launched Ignite, a next-generation data platform in 2024, integrating data from diverse sources, supporting advanced analytics, and migrating all clients to a faster, more cost-effective infrastructure.
AI-driven solutions automate data engineering, patient communication, visualization, chart abstraction, and cybersecurity audits, improving efficiency and accuracy.
Five key focus areas: Ignite platform, measures and registries, clinical improvement, revenue and cost improvement, and ambulatory operations.
Recent acquisitions, including Upfront Healthcare and Intraprise, expand capabilities in patient engagement and cybersecurity.
Over 300 published case studies and billions in documented client financial improvements, including $33M+ margin impact at Allina Health, $10M+ in population health at Carle Health, and $75M+ annual revenue at MultiCare Health System.
Financial performance and outlook
Preliminary 2024 results: $305.7M–$306.7M revenue (+3% YoY), $194M–$195M tech revenue (+4%), $26.1M adjusted EBITDA (+137%, 9% margin).
2025 guidance: ~$335M revenue (+10%), ~$220M tech revenue (+13%), ~$39M adjusted EBITDA (+49%, 12% margin); tech business unit margin expected at 17%.
2028 targets: ~$500M revenue, ~$100M adjusted EBITDA, with two-thirds from technology and a 20% company-wide EBITDA margin; tech BU margin targeted at 30%.
Net new platform clients grew by 91% in 2024 (21 added), with a target of ~40 new clients in 2025; total platform and app clients now exceed 1,000.
Operating expenses declining as a percentage of revenue, with continued positive Adjusted EBITDA trends.
Latest events from Health Catalyst
- 2025 revenue rose 1% to $311.1M, but net loss deepened on large impairment charges.HCAT
Q4 202512 Mar 2026 - Q2 revenue up 4% to $75.9M, EBITDA rose, and net loss narrowed on strong bookings.HCAT
Q2 20242 Feb 2026 - Record client growth and higher margins set the stage for double-digit gains in 2025.HCAT
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 revenue up 3% to $76.4M, net loss narrows, and 2024 outlook raised for growth.HCAT
Q3 202416 Jan 2026 - Pre-pandemic demand, Ignite-driven growth, and margin expansion set up a return to double-digit growth.HCAT
7th Annual Evercore ISI HealthCONx Conference11 Jan 2026 - Tripled revenue, tech focus, and AI-driven efficiency set up 40% annual EBITDA growth.HCAT
Raymond James & Associates’ 46th Annual Institutional Investors Conference26 Dec 2025 - 2025 outlook targets $335M revenue, 13% tech growth, and 40 new platform clients.HCAT
Q4 20242 Dec 2025 - Board seeks approval for director elections, auditor, executive pay, and board declassification.HCAT
Proxy Filing1 Dec 2025 - Board elections, auditor ratification, and executive pay up for vote; strong governance and ESG focus.HCAT
Proxy Filing1 Dec 2025